Mass Vaccination in a Pandemic - Benefits versus Risks Interview with Geert Vanden Bossche

Highlighting the principle of using a prophylactic vaccine in the midst of a pandemic. Likely to create more more viral variants in the process. Timecodes: 0:00​ - Intro 7:36​ - Lockdowns 8:51​ - Gaining immunity from exposure & immunological escape 11:17​ - COVID vaccine 18:30​ - COVID antibodies 19:55​ - NK Cells 25:00​ - Antigen-specific antibodies outcompete natural antibodies 28:51​ - Highly-infectious strain 31:01​ - Vaccine resistance in COVID pandemic 31:51​ - More on immunological escape 32:59​ - Geert Vanden Bossche’s thoughts on COVID vaccination Geert Vanden Bossche PhD, is an internationally recognised vaccine developer having worked as the head of the Vaccine Development Office at the German Centre for Infection Research. Coordinated Global Alliance for Vaccines and Immunisation's Ebola Vaccine Program and contributed to the implementation of an integrated vaccine work plan in collaboration with Global Health Partners (WHO, Bill & Melinda Gates Foundation, CDC, UNICEF), regulators (FDA) and vaccine manufacturers to enable timely deployment or stockpiling of Ebola vaccine candidates. Sharing his perspective on mass vaccination in COVID-19.